Department of Medicine, Louisiana State University Health-Shreveport, Shreveport, LA 71130, USA.
Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA.
Int J Environ Res Public Health. 2021 Oct 21;18(21):11045. doi: 10.3390/ijerph182111045.
The purpose of this pilot study was to assess Chronic Myeloid Leukemia (CML) patients' adherence to, beliefs about, and barriers to oral anticancer agents (OAC) using brief self-report measures in community-based cancer clinics. Patients completed a structured interview including a health literacy assessment, a Brief Medication Questionnaire, two single-item self-report adherence questions, and the Medications Adherence Reasons Scale. Of the 86 participants, 88.4% were white; 55.8% male; mean age, 58.7 years; and 22.1% had limited health literacy. Nonadherence (missing at least one dose in the last week) was reported by 18.6% of participants and associated ( < 0.003) with less-than-excellent perceived ability to take CML medications (16.3%). Black participants reported more difficulty taking CML medications than white participants (28.6% vs. 8.3%, = 0.053). Among all participants, 43.0% reported their CML medicine was ineffective and 24.4% that taking CML pills was somewhat to very hard. The most common reasons for missing a dose were simply missed it (24.4%) and side effects (18.6%). Most patients perceived their ability to take CML medication was good to excellent, yet nearly one in five reported missing at least one dose in the last week. Brief, no-cost self-report assessments to screen CML patients' OAC adherence, barriers, and beliefs could facilitate counseling in busy community cancer clinics.
本初步研究旨在通过在社区癌症诊所使用简短的自我报告措施，评估慢性髓性白血病 (CML) 患者对口服抗癌药物 (OAC) 的依从性、信念和障碍。患者完成了一项结构化访谈，包括健康素养评估、简短药物问卷、两个单项自我报告依从性问题和药物依从性原因量表。在 86 名参与者中，88.4%为白人；55.8%为男性；平均年龄为 58.7 岁；22.1%的人健康素养有限。18.6%的参与者报告存在不依从性（在过去一周内漏服至少一剂），且与较差的（<0.003）自我感知服用 CML 药物的能力有关（16.3%）。黑人参与者报告服用 CML 药物比白人参与者更困难（28.6%比 8.3%， = 0.053）。在所有参与者中，43.0%的人报告 CML 药物无效，24.4%的人认为服用 CML 药丸有点到非常困难。错过剂量的最常见原因是简单地错过了（24.4%）和副作用（18.6%）。大多数患者认为自己服用 CML 药物的能力良好至优秀，但近五分之一的人报告在过去一周内漏服至少一剂。简短、无成本的自我报告评估可以筛选 CML 患者的 OAC 依从性、障碍和信念，从而促进繁忙的社区癌症诊所的咨询。
